Comparative Pharmacology
Head-to-head clinical analysis: CARDIOQUIN versus QUINIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOQUIN versus QUINIDEX.
CARDIOQUIN vs QUINIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent